Analyst Reco. Virpax Pharmaceuticals, Inc.

Equities

Delayed Nasdaq Other stock markets 01:03:50 2024-04-29 pm EDT			5-day change	1st Jan Change
2.83 ^USD	-8.71%		-14.24%	-11.59%

Mar. 26	Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 15	Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs	MT

Analysis-Biotech IPOs to bloom with spotlight on startups with human trial data	23-02-13	RE
Maxim Group Initiates Coverage on Virpax Pharmaceuticals With Buy Rating, $4 Price Target	22-06-09	MT

No results for this search